癫痫持续状态住院患者的治疗进展、疾病难治性与疾病负担的关联
IMPORTANCE: Status epilepticus (SE) is associated with poor clinical outcomes and high cost. Increased levels of refractory SE require treatment with additional medications and carry increased morbidity and mortality, but the associations between SE refractoriness, clinical outco…
要点
- 高难治性癫痫持续状态住院死亡率18.9%,显著高于中难治性6.3%和低难治性4.6%。
- 防止癫痫持续状态进展为难治状态可能改善结局并降低费用。
核心结论
- 癫痫持续状态对美国患者和医疗系统造成巨大负担,死亡率和费用随疾病难治性增加而升高。
- 预防癫痫持续状态进展为更難治状态的干预措施可能改善结局并降低费用。
研究设计与样本
- 按住院期间抗癫痫药物给药情况分为低难治性(无或1种静脉抗癫痫药)、中难治性(>1种静脉抗癫痫药)、高难治性(≥1种静脉抗癫痫药且>1种静脉麻醉药并入住ICU)。
主要发现
- 总体院内死亡率11.2%,高难治性18.9%,中难治性6.3%,低难治性4.6%(所有比较P < .001)。
- 中位住院天数总体5天(IQR 2-10),高难治性8天(IQR 4-15),中难治性4天(IQR 2-8),低难治性3天(IQR 2-5)(所有比较P < .001)。
临床怎么用
- 临床应关注癫痫持续状态患者的难治性进展,高难治性患者死亡率和费用显著更高。
- 早期干预以防止癫痫持续状态进展为难治状态,可能改善结局并降低医疗费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Status epilepticus (SE) is associated with poor clinical outcomes and high cost. Increased levels of refractory SE require treatment with additional medications and carry increased morbidity and mortality, but the associations between SE refractoriness, clinical outcomes, and cost remain poorly characterized. OBJECTIVE: To examine differences in clinical outcomes and costs associated with hospitalization for SE of varying refractoriness. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study of 43 988 US hospitalizations from January 1, 2016 to December 31, 2018, was conducted, including patients with primary or secondary International Statistical Classification of Diseases, Tenth Revision, diagnosis specifying "with status epilepticus." EXPOSURE: Patients were categorized by administration of antiseizure drugs given during hospitalization. Low refractoriness denoted treatment with none or 1 intravenous antiseizure drug. Moderate refractoriness denoted treatment with more than 1 intravenous antiseizure drug. High refractoriness denoted treatment with 1 or more intravenous antiseizure drug, more than 1 intravenous anesthetic, and intensive care unit admission. MAIN OUTCOMES AND MEASURES: Outcomes included discharge disposition, hospital length of stay, intensive care unit length of stay, hospital-acquired conditions, and cost (total and per diem). RESULTS: Among 43 988 hospitalizations for SE, 22 851 patients (51.9%) were male; mean age was 49.9 years (95% CI, 49.7-50.1 years). There were 14 694 admissions (33.4%) for low refractory, 10 140 (23.1%) for moderate refractory, and 19 154 (43.5%) for highly refractory SE. In-hospital mortality was 11.2% overall, with the highest rates among patients with highly (18.9%) compared with moderate (6.3%) and low (4.6%) refractory SE (P < .001 for all comparisons). Median hospital length of stay was 5 days (interquartile range [IQR], 2-10 days) with greater length of stay in highly (8 days; IQR, 4-15 days) compared with moderate (4 days; IQR, 2-8 days) and low (3 days; IQR, 2-5 days) refractory SE (P < .001 for all comparisons). Patients with highly refractory SE also had greater hospital costs, with median costs of $25 105 (mean [SD], $41 858 [$59 063]) in the high, $10 592 (mean [SD], $18 328 [$30 776]) in the moderate, and $6812 (mean [SD], $11 532 [$17 228]) in the low refractory cohorts (P < .001 for all comparisons). CONCLUSIONS AND RELEVANCE: Status epilepticus apparently continues to be associated with a large burden on patients and the US health system, with high mortality and costs that increase with disease refractoriness. Interventions that prevent SE from progressing to a more refractory state may have the potential to improve outcomes and lower costs associated with this neurologic condition.
引用
- Guterman EL, Betjemann JP, Aimetti A, et al. Association Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus. JAMA Neurol. 2021. PMID: 33818596. doi:10.1001/jamaneurol.2021.0520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。